New Global Survey by Johnson & Johnson Finds Most Women Don't Connect Eye Health Changes with MenopauseBusiness Wire • 10/01/26
5 High-Yield Dividend Stocks That Pass the Coverage Test (Not Just the Yield Test)24/7 Wall Street • 10/01/26
History Says Johnson & Johnson Beats Medtronic. Here's Why I'd Still Consider MDT for the Next Decade.The Motley Fool • 10/01/26
3 Reasons Johnson & Johnson Is Still a Buy With Its Stock Near a Record HighThe Motley Fool • 09/30/26
Johnson & Johnson Gears Up For Q3 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate AnalystsBenzinga • 09/30/26
Johnson & Johnson (JNJ) Sees a More Significant Dip Than Broader Market: Some Facts to KnowZacks Investment Research • 09/29/26
Johnson & Johnson's psoriasis drug Icotyde could hit $4.5B in peak sales, BofA saysProactive Investors • 09/29/26
Johnson & Johnson (JNJ) is Attracting Investor Attention: Here is What You Should KnowZacks Investment Research • 09/29/26
Johnson & Johnson presents new data reinforcing sustained disease control and improved daily function achieved with IMAAVY® (nipocalimab-aahu) in generalized myasthenia gravis (gMG)PRNewsWire • 09/29/26
Living Off Dividends at 65: 3 Stocks That Raised Payouts for Longer Than 30 Years24/7 Wall Street • 09/29/26
Want Bulletproof Dividend Income? These 3 Stocks Have Raised Payouts Through 8 Major Downturns24/7 Wall Street • 09/26/26
AbbVie vs. Johnson & Johnson: Which Healthcare Stock Is a Better Buy in 2026?The Motley Fool • 09/25/26
ABBV vs. JNJ: One of These Dividend Aristocrats Will Crush the Other Over the Next Decade24/7 Wall Street • 09/25/26
Johnson & Johnson says Tremfya eases spinal pain in Phase 4 psoriatic arthritis studyProactive Investors • 09/25/26
Johnson & Johnson announces TREMFYA® (guselkumab) is the first and only IL-23 inhibitor to show significant improvement in spinal pain and stiffness in landmark axial psoriatic arthritis (PsA) studyPRNewsWire • 09/25/26